MINT-DICLOFENAC SOLUTION

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

DICLOFENAC SODIUM

Доступна з:

MINT PHARMACEUTICALS INC

Код атс:

S01BC03

ІПН (Міжнародна Ім'я):

DICLOFENAC

Дозування:

0.1%

Фармацевтична форма:

SOLUTION

Склад:

DICLOFENAC SODIUM 0.1%

Адміністрація маршрут:

OPHTHALMIC

Одиниць в упаковці:

5ML/10ML

Тип рецепту:

Prescription

Терапевтична области:

NONSTEROIDAL ANTI-INFLAMMATORY AGENTS

Огляд продуктів:

Active ingredient group (AIG) number: 0114417004; AHFS:

Статус Авторизація:

APPROVED

Дата Авторизація:

2018-04-27

Характеристики продукта

_ _
_ _
_Page 1 of 24_
PRODUCT MONOGRAPH
PR
MINT-DICLOFENAC
Diclofenac Sodium Ophthalmic Solution
0.1% w/v
(House Standard)
Anti-inflammatory Analgesic Agent
Mint Pharmaceuticals Inc.
1093 Meyerside Drive, Unit 1
Mississauga, Ontario
L5T 1J6
www.mintpharmaceuticals.com
Date of Preparation:
April 26, 2018
Submission Control No: 200405
_ _
_ _
_ _
_Page 2 of 24_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................7
OVERDOSAGE
..................................................................................................................8
ACTION AND CLINICAL PHARMACOLOGY
..............................................................8
STORAGE AND STABILITY
............................................................................................9
SPECIAL HANDLING INSTRUCTIONS
.........................................................................9
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................9
PART II: SCIENTIFIC INFORMATION
...............................................................................10
PHARMACEUTICAL INFORMATION
..........................................................................10
CLINICAL TRIALS
.............